Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, for about $14.6 billion, the company said.

An unconventional law firm partnership announced Monday shows how attorneys are seeking the benefits of a merger without ...

A Simpson Thacher & Bartlett partner is leaving after less than three months at the firm to join his mentor Dave Grubman, who is now co-leading Sidley Austin’s global mergers and acquisitions practice ...

Disability discrimination claims from neurodiverse employees with conditions like autism are growing along with increased ...

Corporate programs designed to boost diversity, equity, and inclusion are poised to encounter further legal threats this year ...

In a social media fracas over H-1B visas around the holidays, Elon Musk cast himself as a foil to fellow MAGA supporters of ...

A list of pharmaceutical representatives at the table when the Biden administration negotiated Medicare drug prices reveals ...

In the closing weeks of the Biden administration the US Labor Department’s wage division has closed a flurry of cases involving employer retaliation, violations of overtime pay, and illegal child ...

Companies are tailoring their noncompetes and seeking alternatives in response to state-level restrictions, even as the fate ...

The Department of Health and Human Services’ first major revamp in two decades to its cybersecurity rules would require the ...

Two disputes concerning blank-check companies linked to President-elect Donald Trump’s Truth Social platform and, separately, ...

Stinson’s Renée Steinle says potential audits, workplace raids, and elimination of immigration programs will pose risks to ...